Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2024;74:229–63.
Chow LQM. Head and Neck Cancer. N Engl J Med. 2020;382:60–72.
Google Scholar
Chen Z, Viswanathan R, Morgan EL, Jeon J, Waes CV. Proinflammatory Signaling Pathways and Genomic Signatures in Head and Neck Cancers. In: Early detection and treatment of head & neck cancers. 2021;143–84.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6:92.
Google Scholar
Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci. 1986;83:5233–7.
Google Scholar
Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci. 1989;86:10104–7.
Google Scholar
Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203–34.
Google Scholar
Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell. 2017;168:37–57.
Google Scholar
Holbrook J, Lara-Reyna S, Jarosz-Griffiths H, McDermott MF. Tumour necrosis factor signalling in health and disease. F1000research. 2019;8:F1000.
Google Scholar
Almeida LO, Abrahao AC, Rosselli-Murai LK, Giudice FS, Zagni C, Leopoldino AM, et al. NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio. 2014;4:96–104.
Google Scholar
Yang X, Cheng H, Chen J, Wang R, Saleh A, Si H, et al. Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways. Cancer Immunol Res. 2019;7:1760–74.
Google Scholar
Hu Z, Viswanathan R, Cheng H, Chen J, Yang X, Huynh A, et al. Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers. Mol Cancer Res Mcr. 2021;20:867–82.
Network CGA. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–82.
Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018;23:194–212.e6.
Google Scholar
Morgan EL, Macdonald A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFκB-IL-6 signalling axis. PLoS Pathog. 2019;15:e1007835.
Google Scholar
Morgan EL, Toni T, Viswanathan R, Robbins Y, Yang X, Cheng H, et al. Inhibition of USP14 promotes TNFα-induced cell death in head and neck squamous cell carcinoma (HNSCC). Cell Death Differ. 2023;30:1382–96.
Google Scholar
Pimentel JM, Zhou J-Y, Wu GS. The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers. 2023;15:2752.
Google Scholar
Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ. 2023;30:237–49.
Google Scholar
Kocab AJ, Duckett CS. Inhibitor of apoptosis proteins as intracellular signaling intermediates. FEBS J. 2016;283:221–31.
Google Scholar
Hanifeh M, Ataei F. XIAP as a multifaceted molecule in Cellular Signaling. Apoptosis. 2022;27:441–53.
Google Scholar
Nguyen HT, Tang W, Webster ALH, Whiteaker JR, Chandler CM, Errazquin R, et al. Fanconi anemia-isogenic head and neck cancer cell line pairs: A basic and translational science resource. Int J Cancer. 2023;153:183–96.
Google Scholar
Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases*. J Biol Chem. 1998;273:7787–90.
Google Scholar
Patterson MR, Meijers AS, Ryder EL, Wootton LM, Scarth JA, Evans D, et al. E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer. Oncogene. 2024;43:2184–98.
Google Scholar
Li Y, Patterson MR, Morgan EL, Wasson CW, Ryder EL, Barba-Moreno D, et al. CREB1 activation promotes human papillomavirus oncogene expression and cervical cancer cell transformation. J Méd Virol. 2023;95:e29025.
Google Scholar
Morgan EL, Saleh AD, Cornelius S, Carlson SG, Toni T, Cheng H, et al. Functional RNAi Screening Identifies G2/M and Kinetochore Components as Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma. Cancer Res Commun. 2024;4:2903–18.
Google Scholar
Scarth JA, Wasson CW, Patterson MR, Evans D, Barba-Moreno D, Carden H, et al. Exploitation of ATP-sensitive potassium ion (KATP) channels by HPV promotes cervical cancer cell proliferation by contributing to MAPK/AP-1 signalling. Oncogene. 2023;42:2558–77.
Google Scholar
Chou T-C. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharm Rev. 2006;58:621–81.
Google Scholar
Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W493.
Google Scholar
Raulf N, El-Attar R, Kulms D, Lecis D, Delia D, Walczak H, et al. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10. Br J Cancer. 2014;111:1955–64.
Google Scholar
Xiao R, An Y, Ye W, Derakhshan A, Cheng H, Yang X, et al. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV- and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy. Clin Cancer Res. 2019;25:6463–74.
Google Scholar
Chang C-C, Kuan C-P, Lin J-Y, Lai J-S, Ho T-F, Tanshinone IIA. Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines. Chem Res Toxicol. 2015;28:1574–83.
Google Scholar
Dilshara MG, Jayasooriya RGPT, Molagoda IMN, et al. Silibinin sensitizes TRAIL-mediated apoptosis by upregulating DR5 through ROS-induced endoplasmic reticulum stress-Ca2 + -CaMKII-Sp1 pathway. Oncotarget. 2017;9:10324–42.
Google Scholar
Stein SJ, Baldwin AS. NF-κB Suppresses ROS Levels in BCR-ABL+ Cells to Prevent Activation of JNK and Cell Death. Oncogene. 2011;30:4557–66.
Google Scholar
Morgan MJ, Liu Z. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 2011;21:103–15.
Google Scholar
Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J, et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ. 2014;21:612–23.
Google Scholar
Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, et al. Inhibition of JNK activation through NF-κB target genes. Nature. 2001;414:313–7.
Google Scholar
Fu L, Lin Y-D, Elrod HA, Yue P, Oh Y, Li B, et al. c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer. 2010;9:315.
Google Scholar
Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev MMBR. 2006;70:1061–95.
Google Scholar
Morgan EL, Scarth JA, Patterson MR, Wasson CW, Hemingway GC, Barba-Moreno D, et al. E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer. Cell Death Differ. 2021;28:1669–87.
Google Scholar
Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012;19:140–54.
Google Scholar
Jones PL, Ping D, Boss JM. Tumor Necrosis Factor Alpha and Interleukin-1β Regulate the Murine Manganese Superoxide Dismutase Gene Through a Complex Intronic Enhancer Involving C/EBP-β and NF-κB. Mol Cell Biol. 1997;17:6970–81.
Google Scholar
Stehlik C, Martin R, de, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998;188:211–6.
Google Scholar
Sun Q, Zheng X, Zhang L, Yu J. Smac Modulates Chemosensitivity in Head and Neck Cancer Cells through the Mitochondrial Apoptotic Pathway. Clin Cancer Res. 2011;17:2361–72.
Google Scholar
Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, et al. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma. Radiother Oncol J Eur Soc Therapeut Radiol Oncol. 2015;116:495–503.
Google Scholar
Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, et al. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2. Cancer Res. 2016;76:5442–54.
Google Scholar
Yang L, Kumar B, Shen C, Zhao S, Blakaj D, Li T, et al. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma. Mol Cancer Therapeut. 2019;18:1025–35.
Google Scholar
Schmitt NC, Stokes WA, Bates JE, Kinney BLC, Remick J, McDonald MW, et al. Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer. Clin Cancer Res J Am Assoc Cancer Res. 2025;31:2910–8.
Google Scholar
Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Waes CV, et al. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. Oncoimmunology. 2020;9:1710398.
Google Scholar
Sun X-S, Tao Y, Tourneau CL, Pointreau Y, Sire C, Kaminsky M-C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020;21:1173–87.
Google Scholar
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131:669–81.
Google Scholar
Morgan EL, Patterson MR, Barba-Moreno D, Scarth JA, Wilson A, Macdonald A. The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer. Oncogene. 2021;40:2112–29.
Google Scholar
Soave CL, Guerin T, Liu J, Dou QP. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev. 2017;36:717–36.
Google Scholar
Lai KP, Chen J, Tse WKF. Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy. Int J Mol Sci. 2020;21:2548.
Google Scholar
Wootton LM, Morgan EL. Ubiquitin and ubiquitin-like proteins in HPV-driven carcinogenesis. Oncogene. 2025;44:713–23.
Google Scholar
Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis. 2009;14:607–23.
Google Scholar
Trivedi R, Mishra DP. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol. 2015;5:69.
Google Scholar
Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, et al. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism. Cell Death Dis. 2014;5:e1489–e1489.
Google Scholar
Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol. 2014;8:1220–30.
Google Scholar
Cui Z, Dabas H, Leonard BC, Shiah JV, Grandis JR, Johnson DE. Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. Cell Death Dis. 2021;12:775.
Google Scholar
Shlyakhtina Y, Pavet V, Gronemeyer H. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Cell Death Dis. 2017;8:e3025–e3025.
Google Scholar
Sung E-S, Park K-J, Choi H-J, Kim C-H, Kim Y-S. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res. 2012;318:1564–76.
Google Scholar
Sarhan D, Wennerberg E, D’Arcy P, Gurajada D, Linder S, Lundqvist A. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunol Immunother. 2013;62:1359–68.
Google Scholar
Oh Y-T, Deng L, Deng J, Sun S-Y. The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Sci Rep-uk. 2017;7:8027.
Qiao X, Guo S, Meng Z, Gan H, Wu Z, Sun Y, et al. Advances in the study of death receptor 5. Front Pharm. 2025;16:1549808.
Google Scholar
Cai J, Xia X, Liao Y, Liu N, Guo Z, Chen J, et al. A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers. Oncotarget. 2017;8:63232–46.
Google Scholar
Zhang X, Espinosa B, Saei AA, D’Arcy P, Zubarev RA, Linder S. Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment. Oxid Med Cell Longev. 2019;2019:1659468.
Google Scholar
Ding W, Wang J, Wu J, Liu A, Jiang L, Zhang H, et al. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. Acta Pharm Sin. 2023;44:2537–48.
Google Scholar
Brnjic S, Mazurkiewicz M, Fryknäs M, Sun C, Zhang X, Larsson R, et al. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxid Redox Signal. 2013;21:2271–85.
Google Scholar
An Y, Jeon J, Sun L, Derakhshan A, Chen J, Carlson S, et al. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. Sci Rep. 2021;11:6392.
Google Scholar
Kaur S, Wang F, Venkatraman M, Arsura M. X-linked Inhibitor of Apoptosis (XIAP) Inhibits c-Jun N-terminal Kinase 1 (JNK1) Activation by Transforming Growth Factor β1 (TGF-β1) through Ubiquitin-mediated Proteosomal Degradation of the TGF-β1-activated Kinase 1 (TAK1). J Biol Chem. 2005;280:38599–608.
Google Scholar
Fan H, Liu J, Hu X, Cai J, Su B, Jiang J. The critical role of X-linked inhibitor of apoptosis protein (XIAP) in tumor development. Apoptosis. 2025;30:1202–15.
Google Scholar
Saraei R, Soleimani M, Akbari AAM, Hagh MF, Hassanzadeh A, Solali S. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia. Biomed Pharmacother. 2018;107:1010–9.
Google Scholar
Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, et al. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode. Cell Death Dis. 2013;4:e643–e643.
Google Scholar
Toni T, Viswanathan R, Robbins Y, Gunti S, Yang X, Huynh A, et al. Combined Inhibition of IAPs and WEE1 Enhances TNFα- and Radiation-Induced Cell Death in Head and Neck Squamous Carcinoma. Cancers. 2023;15:1029.
Google Scholar
Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, et al. Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia. J Clin Oncol. 2009;27:4741–6.
Google Scholar
Carlet M, Schmelz K, Vergalli J, Herold T, Senft D, Jurinovic V, et al. X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL. EMBO Mol Med. 2023;15:EMMM202114557.
